Cell therapy for SLE

The Institute has developed and implemented a method for the treatment of systemic lupus erythematosus (SLE) using a unique biomedical cell product (BMCP) based on allogeneic pooled MSCs of the olfactory lining.

The use of this BMCP is safe and allows you to effectively:

suppress the formation of antibodies to one’s own tissues and normalize the patient’s immune status;
slow down the processes of damage to internal organs and promote the restoration of their functional activity;
normalize coagulogram and lipid profile, transaminases and liver markers;
reduce doses of basic therapy drugs;
increase the duration of remission and reduce the frequency of relapses;
Ultimately, the use of this BMCP improves the quality of life of patients and prevents disability.

For additional information and to make an appointment with specialists, please call the following phone numbers:

+375 (17) 378 18 21
+375 (44) 574 18 21 (Viber, WhatsApp, Telegram)
e-mail: med@ibce.by